HealthPulse's Comment to CMS

Does the Medicaid community engagement (work) requirement's eligibility-verification cadence create a structural risk of interrupting continuous Medicaid enrollment, claims, and registry data for beneficiaries in an active Cell and Gene Therapy (CGT) Access Model treatment episode, and if so, what continuity safeguards would protect both federal priorities?

The Interim Final Rule with Comment Period (CMS-2454-IFC, 91 FR 33348); CMS's Cell and Gene Therapy Access Model program design, FAQ materials, and Billing Information Guide; CIBMTR/CMMI registry documentation; state-level CGT coverage and billing guidance from Illinois, North Carolina, Connecticut, New York, Pennsylvania, and Texas; a published account of the 2018 Arkansas Medicaid work-requirement coverage loss (KFF); federal confirmation of 2023 Medicaid "unwinding" computer-system errors (Associated Press); Rural Health Transformation Program materials.

Regulatory and program-document analysis tracing a defined causal chain: eligibility continuity, then claims and registry continuity, then outcomes-based agreement (OBA) measurement integrity, then rebate reconciliation. This chain is cross-referenced against state-specific CGT billing and coverage mechanics in six CGT Access Model participating states, and against two documented instances of administrative, non-clinical Medicaid coverage loss at scale.

The comment does not assert that either the Arkansas or the 2023 unwinding example predicts the scale of CGT-specific disruption. Both are offered only to establish that administrative coverage loss at scale is a documented general phenomenon, not a CGT-specific measurement. The comment does not offer a quantified estimate of per-state Medicaid revenue exposure. It requests sub-regulatory clarification; CMS is not obligated to respond given the interim-final-rule posture.

That the CGT Access Model's measurement design and the community engagement requirement's verification cadence can structurally intersect within a single treatment episode, based on CMS's own published program mechanics and rule text.

That without specific continuity guidance, an administrative eligibility lapse during an active CGT episode could disrupt claims and registry continuity in a way that degrades outcomes-based rebate measurement, independent of whether any given beneficiary is actually ineligible.

That this interruption has occurred, or will occur at any specific rate, for any specific state, beneficiary, or manufacturer agreement. The comment presents no claims-level or beneficiary-level data demonstrating an actual occurrence.

State-level, longitudinal data connecting redetermination timing to CGT Access Model beneficiary coverage continuity and OBA data completeness. This data would only become available as states implement the community engagement requirement and as CMS or states begin tracking outcomes.

• Recognize an active, acute CGT treatment episode as strong evidence supporting the rule's two-part medically-frail exemption, usable ex parte.
• Clarify that states may use diagnosis and treatment-phase claims data to identify Model beneficiaries for exemption review ex parte.
• Provide guidance protecting the OBA measurement window when a redetermination falls mid-episode.
• Affirm that work-requirement administrative noncompliance is categorically distinct from clinical or medical noncompliance.
• Clarify continuity expectations for beneficiaries treated at out-of-state qualified treatment centers.

None of these requests requires amending the rule text, creating a new eligibility category, or expanding the five statutory medically-frail categories.